Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;70(6):1920-1930.
doi: 10.4103/ijo.IJO_2239_21.

Newer advances in medical management of glaucoma

Neethu Mohan  1 , Arup Chakrabarti  2 , Nazneen Nazm  3 , Rajvi Mehta  4 , Deepak P Edward  5
Affiliations
Review

Newer advances in medical management of glaucoma

Neethu Mohan et al. Indian J Ophthalmol. 2022 Jun.

Abstract

The burden of irreversible vision loss from Glaucoma continues to rise. While the disease pathogenesis is not well understood, intraocular pressure (IOP) is the only modifiable risk factor identified to prevent glaucomatous vision loss. Medical management remains the first-line of treatment in most adult glaucomas and the evolution of medical therapy for glaucoma has followed an exponential curve. This review tracks the rapid development of new medications and drug delivery systems in the recent years. Introduction of Rho kinase inhibitors with an entirely new mechanism of action from that of the currently used anti glaucoma medications has been a significant milestone. Latanoprostene Bunod is a novel, single molecule which provides two active metabolites that work through two different pathways for reducing intra ocular pressure. Bimatoprost implants and travoprost punctum plugs attempt to ease chronic medication use in glaucoma patients. Nanotechnology is an evolving route of drug delivery. Role of cannabinoids in medical management of glaucoma remain equivocal. The relatively short term effect on IOP, the risks of developing tolerance and side effects impacting patients' neurocognitive health greatly outweigh the potential benefit. Research on Latrunculin B, Adenosine receptor agonists, Specific gene silencing and Stem cell therapy are poised to make an impact on glaucoma treatment. While there is some evidence to support the role of Brimonidine in neuroprotection, further research is needed to clarify the role of Memantine and Neurotrophins. Evidence for benefit from dietary supplementation with Alpha lipoic acid, Forskolin , and Ginko Biloba is limited.

Keywords: Adenosine receptor agonists; bimatroprost ring; cannabinoids; drug delivery systems; glaucoma; latanoprostene bunod; latrunculins; liposomes; medical management; nano particles; prostaglandin analogue; punctal plug; rho kinase inhibitors; surgical implants; sustained release.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Latanoprost acid (1) and nitric oxide (2) – the two active metabolites of LBN
Figure 2
Figure 2
Neuroprotection in glaucoma
Figure 3
Figure 3
New glaucoma medications at various stages of development
See this image and copyright information in PMC

References

    1. Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040:A systematic review and meta-analysis. Ophthalmology. 2014;121:2081–90. - PubMed
    1. Kopczynski CC, Epstein DL. Emerging trabecular outflow drugs. J Ocul Pharmacol Ther. 2014;30:85–7. - PMC - PubMed
    1. Tanna AP, Johnson M. Rho Kinase inhibitors as a novel treatment for glaucoma and ocular hypertension. Ophthalmology. 2018;125:1741–56. - PMC - PubMed
    1. Thieme H, Nuskovski M, Nass JU, Pleyer U, Strauss O, Wiederholt M. Mediation of calcium-independent contraction in trabecular meshwork through protein kinase C and rho-A. Invest Ophthalmol Vis Sci. 2000;41:4240–6. - PubMed
    1. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42:1029–37. - PubMed